Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects

A Pharmacokinetics Study of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects

This is a single-center, randomized, open-label study to evaluate the pharmacokinetics of CM310 in healthy subjects.

This study includes screening and treatment and follow-up periods.

Inclusion Criteria:

• 20 years ≤ age ≤ 45 years.
• Voluntarily participate in the study and sign the ICF.
• Have the ability to understand the study.

Exclusion Criteria:

• With history of chronic or serious illness.
• With any medication within 28 days prior to administration;
• Plan to undergo surgery during the research period;
• With any situations unsuitable to participate in this study.